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Abstract
Background: The objective of this study was to characterize insulin use and examine factors associated with
persistence to mealtime insulin among patients with type 2 diabetes (T2D) on stable basal insulin therapy initiating
mealtime insulin therapy.
Methods: Insulin use among patients with T2D initiating mealtime insulin was investigated using Thomson Reuters
MarketScan® research databases from July 2001 through September 2006. The first mealtime insulin claim
preceded by 6 months with 2 claims for basal insulin was used as the index event. A total of 21 months of
continuous health plan enrollment was required. Patients were required to have a second mealtime insulin claim
during the 12-month follow-up period. Persistence measure 1 defined non-persistence as the presence of a 90-day
gap in mealtime insulin claims, effective the date of the last claim prior to the gap. Persistence measure 2 required
1 claim per quarter to be persistent. Risk factors for non-persistence were assessed using logistic regression.
Results: Patients initiating mealtime insulin (n = 4752; 51% male, mean age = 60.3 years) primarily used vial/
syringe (87%) and insulin analogs (60%). Patients filled a median of 2, 3, and 4 mealtime insulin claims at 3, 6, and
12 months, respectively, with a median time of 76 days between refills. According to measure 1, persistence to
mealtime insulin was 40.7%, 30.2%, and 19.1% at 3, 6, and 12 months, respectively. Results for measure 2 were
considerably higher: 74.3%, 55.3%, and 42.2% of patients were persistent at 3, 6, and 12 months, respectively.
Initiating mealtime insulin with human insulin was a risk factor for non-persistence by both measures (OR < 0.80,
p < 0.01). Additional predictors of non-persistence at 12 months included elderly age, increased insulin copayment,
mental health comorbidity, and polypharmacy (p < 0.05 for all).
Conclusions: Mealtime insulin use and persistence were both considerably lower than expected, and were
significantly lower for human insulin compared to analogs.
Background
For many patients with type 2 diabetes, initiation of
insulin therapy marks the transition of their diabetes
condition into a more severe disease state with the
potential for more complications. The goal of type 2
diabetes treatment is to maintain a glycosylated hemo-
globin (HbA1c) of < 7%, a goal that has been made
easier through advances in insulin types and delivery
options [1]. However, significant barriers still remain in
physicians’ and patients’ minds regarding insulin use.
The Diabetes Control and Complications Trial showed
that patients treated with intensive insulin therapy
demonstrated a 3-fold increased risk of a severe hypo-
glycemia event, a finding that physicians are aware of,
according to Meece [2]. This awareness can therefore be
a factor in clinical inertia for intensifying insulin therapy
when patients are no longer controlled with basal insu-
lin [3,4]. Patient fears regarding possible adverse health
consequences associated with intensifying insulin ther-
apy, such as weight gain or hypoglycemia, also factor
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into adherence to a treatment regimen including meal-
time insulin. For most patients, the addition of mealtime
insulin also requires insulin administration outside the
home, which may have significant lifestyle implications
due to public insulin use and inconveniences associated
with carrying and storing insulin. Persistence with insu-
lin is often low [5]; 16% to 49% of patients are persistent
at 6 to 12 months [5-8]. Research suggests that medica-
tion regimen complexity [7] and higher frequency dos-
ing schedules [9,10] are barriers to taking insulin. Thus,
several treatment-related factors may be significant bar-
riers to successful long-term treatment for some
patients.
The primary objective of this study was to describe
insulin use among patients adding mealtime insulin to
their basal insulin regimen. The secondary objective of
this study was to describe persistence to mealtime insu-
lin and determine risk factors for poor persistence with
insulin therapy. This study employed a retrospective
approach using administrative claims data.
Methods
Two Thomson Reuters MarketScan® research data-
bases were used in this study: the Commercial Claims
and Encounters (Commercial) database and the Medi-
care Supplemental and Coordination of Benefits
(Medicare Supplemental) Database. The Commercial
database contains the inpatient, outpatient, emergency
room, and outpatient prescription drug experience of
several million individuals and their dependents in the
United States. The overall database includes indivi-
duals from over 100 self-insured large employers and
health plans. The Medicare Supplemental database
contains the healthcare experience of individuals with
Medicare supplemental insurance paid for by employ-
ers. The methods used in this current study were
employed in a similar analysis of insulin naïve patients
with type 2 diabetes using the same datasource and
study design [11].
Inclusion criteria
Patients were new mealtime insulin initiators between
July 1, 2001 and December 31, 2006 (index date).
A 6-month pre-period was used to establish new meal-
time insulin use, a diagnosis of type 2 diabetes (identi-
fied by ICD-9-CM codes), and the presence of stable
insulin therapy, as evidenced by having at least 2 claims
for a basal insulin therapy in the 6 months preceding
the index date. Patients had to be enrolled in a qualified
health plan with concurrent continuous pharmacy
enrollment for a 21-month period spanning the
6-month pre-index period through the 15-month study
period between January 1, 2001 and March 31, 2008.
Figure 1 illustrates the study period.
Exclusion criteria
Patients were excluded if they had evidence of gesta-
tional diabetes (ICD-9-CM code 648.8×), type 1 diabetes
(ICD-9-CM code 250. × 1 or 250. × 3, or DRG 295), or
used inhaled insulin or an insulin pump anytime in the
observation period. Patients were also excluded if they
used an insulin mixture in the post-index period.
Patients with only 1 mealtime insulin claim were also
excluded from this analysis.
Insulin Use Variables
Index insulin characteristics such as insulin type (human
versus analog) and administration (pen versus vial/syringe)
were reported. Examples of each insulin type are shown in
table 1. Insulin use variables included:
1) Number of prescription claims for mealtime insu-
lin at 3, 6, and 12 months
2) Number of prescription claims for basal insulin at
3, 6, and 12 months
3) Average daily insulin supply calculated at 3, 6,
and 12 months post-index date by calculating the
total insulin supply in ml dispensed and dividing by
the number of days in that period.
4) Average time between refills of index insulin
5) Proportion that switched to a different insulin
type or administration
6) Presence of a 90-day gap between insulin claims.
Insulin Persistence Measures
This study evaluated persistence with mealtime insulin
at 12 months, defined as the time from mealtime insulin
initiation to discontinuation. Persistence was evaluated
at 12 months by the absence of gaps between refills
(measure 1) or the number of refills within a pre-specified
period (measure 2). Measure 2 was designed as a more
lenient sensitivity analysis to measure 1, which is a stan-
dard definition of persistence [12]. Under measure 1,
patients were considered persistent at 3 months if they did
not have a 90-day gap in index insulin claims that started
prior to the end of the third month. Patients were consid-
ered persistent at 6 and 12 months if they did not have
90-day gaps prior to the end of the relevant time periods.
For example, if a patient had an index claim on January 1
and had refills on March 15, May 1, and July 15 and
no others refills, then the patient would be persistent at
6 months (due to no 90-day gaps prior to July 1) but not
at 12 months.
Measure 2 was defined as follows:
• Persistent at 3 months
◦ At least 2 mealtime insulin claims in first
4 months
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• Persistent at 6 months
◦ At least 3 mealtime insulin claims in first
7 months
▪ At least one mealtime insulin claim in
months 1-3, and
▪ At least one mealtime insulin claim in
months 4-6
• Persistent at 12 months
◦ At least 4 mealtime insulin claims in first
12 months
▪ At least one mealtime insulin claim in
months 1-3, and
▪ At least one mealtime insulin claim in
months 4-6, and
▪ At least one mealtime insulin claim in
months 7-9, and
▪ At least one mealtime insulin claim in
months 10-12
For measure 2, counts of mealtime insulin claims
include the index claim. For example, for a patient to be
Index
Date6-Month Pre-Period 15-Month Follow-up Period
21 months continuous enrollment
2+ Basal insulin scripts 1st mealtime script
1+ Type 2 diabetes dx
Figure 1 Study Period.
Table 1 Insulin Type Classification
Class Generic Name Brand Name Type





Basal Insulin Human Zinc (Lente) HUMULIN L
NOVOLIN L
Human
Basal Insulin Human Zinc, Extended (Ultralente) HUMULIN U Human
Basal Insulin Detemir LEVEMIR Analog
Basal Insulin Glargine, Recombinant LANTUS Analog
Insulin Mixtures Insulin Human Isophane (NPH)/Insulin Human Regular HUMULIN 50/50
HUMULIN 70/30
Human
Insulin Mixtures Insulin Human Isophane (NPH)/Insulin Human Regular NOVOLIN 70/30
RELION NOVOLIN 70/30
Human
Insulin Mixtures Insulin Lispro/Insulin Lispro Protamine HUMALOG MIX 50/50
HUMALOG MIX 75/25
Analog
Insulin Mixtures Insulin Aspart/Insulin Aspart Protamine NOVOLOG MIX 70/30 Analog
Mealtime Insulin Aspart, Recombinant NOVOLOG Analog
Mealtime Insulin Glulisine APIDRA Analog
Mealtime Insulin Lispro, Recombinant HUMALOG
LISPRO-PFC
Analog




Mealtime Insulin Human Regular, Buffered HUMULIN BR
VELOSULIN BR
Human
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persistent at 3 months, they would need to fill at least 1
additional mealtime insulin claim within 4 months fol-
lowing their index claim. Non-persistence, as deter-
mined by these measures, does not imply a permanent
discontinuation from insulin and may be a marker for
intermittent use.
Persistent and non-persistent patients were compared
using standard tests of statistical significance. Chi-square
tests were used to evaluate the statistical significance of
differences for categorical variables; two-tailed t-tests
and analysis of variance were used for continuous vari-
ables. A series of logistic regression models were used
to examine factors associated with being persistent with
insulin therapy at 12 months. Factors included age, gen-
der, location, type of insurance, insulin type, insulin
administration mode, Deyo Charlson Comorbidity Index
[13], presence of hospitalization, presence of emergency
room visit, presence of diabetes complications, presence
of macrovascular complications, presence of mental
health disorders, count of other diabetes medications
and average copayment per claim of insulin. An alpha of
0.05 was used for all analyses.
Results
A total of 294,769 patients who had 1 or more mealtime
insulin claim were identified during the study period. Of
this total, 66,805 (22%) patients had a type 2 diabetes
diagnosis and continuous enrollment. Requiring 2 claims
of basal insulin in the pre-period brought the sample to
19,668. Evidence of type I diabetes caused 13,184 patients
to be excluded. An additional 27 patients were excluded
for a diagnosis of gestational diabetes or for using inhaled
insulin or an insulin pump. This left a total of 6,457
patients on stable basal insulin who initiated a mealtime
insulin regimen. Seven hundred forty-eight (approxi-
mately 12%) of those patients were excluded from further
analysis because they had a claim for an insulin mixture
in the post-index period. Of the remaining 5,709 patients,
957 (14.8%) had a single mealtime claim, leaving 4,752 as
the final sample size of patients with 2 or more mealtime
insulin claims in the post-index period.
Table 2 contains the insulin use characteristics of the
study sample. The average time between refills over
12 months was 94.5 days (median: 75.5 days). The
majority of the sample (80.9%) had a 90-day gap in the
1-year following initiation of mealtime insulin. The
mean time to the start of the 90-day gap was 67.6 days,
and the time between the start of the 90-day gap and
the next claim was 160.0 days. The majority of patients
(86.6%) with a 90-day gap had a claim following the
gap. Persistence was 40.7% at 3 months, 30.2% at
6 months, and 19.1% at 12 months using measure 1.
Persistence was 74.3% at 3 months, 55.3% at 6 months,
and 42.2% at 12 months using measure 2.
In terms of demographics, there were several statisti-
cally significant differences between persistent and non-
persistent patients; however, several of these differences
were not of practical importance. For example, persis-
tent patients were statistically but not substantively
younger than non-persistent patients (measure 1: 58.6
versus 60.7, p < 0.0001; measure 2: 59.7 versus 60.8
years, p = 0.0043). There were also numerous statisti-
cally significant differences between persistent and non-
persistent patients in terms of clinical characteristics.
Table 3 contains comparisons of demographic and clini-
cal characteristics stratified by persistence status. The
mean Deyo Charlson Comorbidity Index score was
lower among persistent patients than non-persistent
patients (measure 1: 2.05 versus 2.22, p = 0.015; mea-
sure 2: 2.10 versus 2.25, p = 0.004). Persistent patients
had lower counts of concomitant diabetes medication
classes than non-persistent patients (measure 1: 0.86
versus 1.05 classes, p < 0.0001; measure 2: 0.94 versus
1.07 classes, p < 0.0001). Persistent patients were also
less likely than non-persistent patients to have diabetes
complications (measure 1: 28.5% versus 32.6%, p =
0.017; measure 2: 29.9% versus 33.2%, p = 0.014),
macrovascular complications (measure 1: 48.4% versus
50.7%, p = 0.215; measure 2: 48.5% versus 51.6%, p =
0.037), and mental health disorders (measure 1: 5.6%
versus 7.4%, p = 0.056; measure 2: 6.2% versus 7.7%,
p = 0.040).
Persistent patients were less likely than non-persistent
patients to use human insulin at index (36.9% versus
42.3%, p < 0.0001) as defined by measure 2. As expected
(by definition of persistence), the number of claims and
quantity per day was higher among persistent patients,
and time between insulin claims was lower among
persistent patients, compared to non-persistent patients.
The mean total cost of claims was higher among persis-
tent patients than non-persistent patients (measure
1: $6,122.81 versus $5,663.12, p = 0.009; measure
2: $6,220.88 versus $5,407.54, p < 0.0001) while the
average copayment per insulin claim was lower (mea-
sure 1: $15.68 versus $18.41, p = 0.007; measure 2:
$16.63 versus $18.81, p = 0.007).
Multivariate Results: Persistence at 12 months
Multivariate results are summarized in Table 4. Gender
was not statistically significantly associated with persis-
tence. Compared to patients 45 to 54 years, those over
age 65 were statistically significantly less likely to be
persistent at 12 months. Living in a rural location was
associated with increased persistence by measure 1 (OR
= 1.26 [95% CI: 1.05, 1.52], p = 0.013) but not by mea-
sure 2 (OR = 1.12 [95% CI: 0.97, 1.31], p = 0.129).
A capitated insurance plan was also not statistically signifi-
cantly associated with insulin persistence at 12 months.
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The use of human insulin was associated with
decreased odds by persistence measures 1 and 2 (OR =
0.80 [95% CI: 0.68, 0.95] and 0.77 [95% CI: 0.67, 0.87],
p < 0.01 for both). The use of an insulin pen was not
statistically significantly associated with persistence at
12 months. None of the clinical characteristics were
associated with insulin persistence at 12 months.
The count of oral antidiabetic (OAD) agents was sta-
tistically significant by measure 2 (OR = 1.04 [95% CI:
1.00, 1.06], p = 0.01), but not by measure 1 (OR = 0.99
[95% CI: 0.96, 1.03], p = 0.601). The average copay-
ment for insulin was a predictor of non-persistence by
persistence measures 1 and 2 (OR = 0.99, p < 0.0001
for both).
Discussion
The majority of patients initiating mealtime insulin had
a 90-day gap in mealtime insulin claims (81%) during
the year following their first mealtime insulin claim.
According to Sikka and colleagues, patients filling claims
following an allowable gap are still considered non-
persistent [14]. However, the presence of a 90-day gap is
not a measure of complete discontinuation; 87% of
patients with a 90-day gap had a mealtime insulin claim
following the gap. Of the 3,843 patients with a 90-day
claim gap, nearly half (46.2%) had a gap immediately fol-
lowing their index claim. Using a 90-day gap to define
insulin persistence increases the likelihood of falsely
classifying persistent patients as non-persistent.
Table 2 Insulin Use Characteristics
Mean Median Interquartile
Range
Number of claims: Mealtime
3 months 1.95 2 (1, 2)
6 months 3.11 3 (2, 4)
12 months 5.32 4 (3, 7)
Number of claims: Basal
3 months 1.93 2 (1, 3)
6 months 3.65 3 (2, 5)
12 months 6.95 6 (4, 10)
Number of claims: Total
3 months 3.89 4 (3, 5)
6 months 6.76 6 (4, 9)
12 months 12.27 11 (8, 15)
Quantity per day (mL): Mealtime
3 months 0.23 0.22 (0.11, 0.33)
6 months 0.19 0.17 (0.11, 0.22)
12 months 0.16 0.14 (0.08, 0.21)
Quantity per day (mL): Basal
3 months 0.22 0.22 (0.11, 0.33)
6 months 0.21 0.17 (0.11, 0.28)
12 months 0.19 0.16 (0.11, 0.27)
Quantity per day (mL): Total
3 months 0.45 0.44 (0.33, 0.56)
6 months 0.39 0.33 (0.28, 0.50)
12 months 0.35 0.33 (0.22, 0.44)
Time between mealtime refills
12 months 94.5 75.5 (48, 116)
Time from index to start of 90-day gap among patients with a 90-day gap N = 3843 (80.9% of total sample)
12 months 67.6 25 (1, 95)
Time between start of 90-day gap and next mealtime script among patients with a mealtime script
following a 90-day gap
N = 3335 (86.8% of patients with a
90-day gap)
12 months 160.0 135 (107, 192)
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Table 3 Demographic and Clinical Characteristics
Persistence Measure 1 Persistence Measure 2 Total
Persistent Non-persistent Persistent Non-persistent
N = 909 N = 3,843 p-value N = 2,007 N = 2,745 p-value N = 4,752
Gender: Female (%) 47.85 49.15 0.481 47.98 49.58 0.276 48.91
Age (mean [SD]) 58.6 (11.8) 60.7 (12.3) <0.0001 59.7 (12.1) 60.8 (12.3) 0.0043 60.3 (12.2)
Age Group (%)
<18 0.22 0.16 <0.0001 0.20 0.15 0.069 0.17
18-34 1.76 1.43 1.54 1.46 1.49
35-44 7.92 6.48 6.78 6.74 6.76
45-54 26.07 22.85 24.76 22.51 23.46
55-64 36.74 33.49 35.33 33.22 34.11
65-74 16.94 20.66 18.73 20.84 19.95
75 and older 10.34 14.94 12.66 15.08 14.06
Location (%)
Urban 77.34 80.61 0.018 79.02 80.69 0.091 79.99
Rural 22.44 18.79 20.63 18.65 19.49
Unknown 0.22 0.60 0.35 0.66 0.53
Insulin Type- index claim (%)
Human 37.62 40.62 0.097 36.92 42.33 <0.0001 40.05
Analog 62.38 59.38 63.08 57.67 59.95
Insulin Administration- index claim (%)
Vials and Syringes 88.01 86.76 0.312 86.70 87.21 0.601 86.99
Pens 11.99 13.24 13.30 12.79 13.01
Change in Index Insulin
Human vs. Analog Change (%) 26.84 28.57 0.298 26.46 29.54 0.020 28.24
Mean time to change (SD) 52.79 (86.30) 57.50 (81.95) 0.421 56.14 (83.32) 56.98 (82.42) 0.856 56.65 (82.75)
Pen vs. vial/syringe change (%) 4.40 3.54 0.216 4.68 2.99 0.002 3.70
Mean time to change (SD) 145.1 (107.34) 154.13 (109.70) 0.646 150.64 (113.69) 153.73 (103.88) 0.852 52.08 (108.93)
Insulin Use: 12 months (mean [SD])
Mealtime Insulin Claims 9.99 (3.36) 4.21 (2.06) <0.0001 7.90 (3.30) 3.43 (1.50) <0.0001 5.32 (3.28)
Basal Insulin Claims 9.64 (4.41) 6.32 (3.65) <0.0001 8.17 (4.24) 6.06 (3.60) <0.0001 6.95 (4.02)
Total Insulin Claims 19.63 (6.42) 10.53 (4.60) <0.0001 16.07 (6.42) 9.49 (4.13) <0.0001 12.27 (6.15)
Mealtime Insulin quantity per day (ml) 0.30 (0.11) 0.13 (0.06) <0.0001 0.23 (0.10) 0.10 (0.05) <0.0001 0.16 (0.10)
Basal Insulin quantity per day (ml) 0.27 (0.13) 0.18 (0.10) <0.0001 0.23 (0.12) 0.17 (0.10) <0.0001 0.19 (0.11)
Total Insulin quantity per day (ml) 0.56 (0.19) 0.30 (0.13) <0.0001 0.46 (0.19) 0.27 (0.12) <0.0001 0.35 (0.18)
Days between Mealtime Insulin Claims 42.44 (13.68) 106.77 (69.27) <0.0001 58.06 (23.98) 121.09 (76.10) <0.0001 94.47 (67.50)
Concomitant Medications Count
Diabetes medications 0.87 (0.91) 1.07 (0.99) <0.0001 0.95 (0.93) 1.09 (1.01) <0.0001 1.03 (0.98)
Cardiovascular medications 4.07 (2.36) 4.23 (2.49) 0.072 4.25 (2.42) 4.17 (2.49) 0.265 4.20 (2.46)
Copayment Burden
Total cost of pharmacy claims $6,122 (5657) $5,663 (4567) 0.009 $6,221 (5310) $5,408 (4355) <0.0001 $5,751 (4798)
Copay per insulin claim $15.68 (12.21) $18.41 (29.82) 0.007 $16.63 (13.20) $18.81 (34.17) 0.007 $17.89 (27.37)
Deyo Charlson Comorbidity Index (mean) 2.05 (1.76) 2.22 (1.82) 0.015 2.10 (1.73) 2.25 (1.86) 0.004 2.19 (1.81)
Comorbidities (%)
Diabetes complications 28.49 32.58 0.017 29.85 33.22 0.014 31.80
Macrovascular complications 48.40 50.69 0.215 48.48 51.55 0.037 50.25
Any mental health 5.61 7.42 0.056 6.18 7.72 0.040 7.70
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According to measure 2, which is more lenient and
allows for sizeable gaps between the required number of
insulin claims, less than half of patients (42%) were per-
sistent at 12 months.
A significant number of patients who met the study
inclusion and exclusion criteria (17%) were excluded
because they only filled their index mealtime insulin
claim. A single mealtime insulin claim may indicate
a response to an acute hyperglycemic event and not
represent a true intensification of diabetes management.
Further investigation of these patients and their reasons
for early discontinuation is warranted.
Several factors could be related to the findings regard-
ing insulin type (analog versus human) and delivery
(pen versus vial/syringe). Previous research has found
that a dislike of injections is related to discontinuing
insulin use [8], which might imply that insulin pens may
have better persistence than vial/syringe due to the
Table 3 Demographic and Clinical Characteristics (Continued)
Diabetes-Related Events
Inpatient Admissions (%) 0.55 1.09 0.294 0.70 1.20 0.124 0.99
Mean length of stay 4.2 (1.48) 7.10 (6.59) 0.337 7.64 (4.81) 6.42 (6.87) 0.550 6.79 (6.30)
ER Use (%) 0.66 0.62 0.903 0.75 0.55 0.388 0.63
Cardiovascular-Related Events
Inpatient Admissions (%) 4.18 5.54 0.381 5.28 5.28 0.675 5.28
Mean length of stay 2.87 (3.83) 4.56 (6.53) 0.124 3.57 (3.15) 4.83 (7.70) 0.112 4.30 (6.22)
ER Use (%) 2.09 2.2% 0.785 2.14 2.26 0.788 2.21
Abbreviation: SD = standard deviation; ER = Emergency Room.
Table 4 Multivariate Analysis
Logistic Regression
Sample Size (N = 4,752) Persistence at 12 months: Measure 1 Persistence at 12 months: Measure 2
OR (95% CI) p-value OR (95% CI) p-value
Female 0.96 (0.83, 1.12) 0.62 0.94 (0.84, 1.06) 0.33
Age < 35 1.04 (0.60, 1.81) 0.89 1.02 (0.64, 1.62) 0.94
Age 35-44 1.06 (0.78, 1.43) 0.72 0.94 (0.73, 1.21) 0.62
Age 55-64 0.96 (0.79, 1.17) 0.69 0.97 (0.83, 1.14) 0.70
Age 65-74 0.73 (0.57, 0.92) 0.01 0.82 (0.68, 0.99) 0.03
Age >74 0.63 (0.48, 0.83) 0.00 0.81 (0.65, 0.99) 0.04
Region: North Central 0.84 (0.64, 1.10) 0.20 0.85 (0.68, 1.06) 0.15
Region: South 0.85 (0.65, 1.11) 0.24 0.81 (0.65, 1.01) 0.06
Region: West 0.80 (0.60, 1.07) 0.13 0.81 (0.64, 1.02) 0.07
Region: Unknown 0.31 (0.07, 1.33) 0.12 0.42 (0.17, 1.02) 0.06
Rural 1.26 (1.05, 1.52) 0.01 1.12 (0.97, 1.31) 0.13
Capitated Insurance 1.18 (0.98, 1.43) 0.08 1.04 (0.89, 1.21) 0.62
Index: Human 0.80 (0.68, 0.95) 0.01 0.77 (0.67, 0.87) <0.0001
Index: Pen 0.86 (0.68, 1.08) 0.21 0.98 (0.82, 1.17) 0.79
Deyo Charlson Com. Index 0.99 (0.94, 1.04) 0.67 0.97 (0.93, 1.01) 0.11
ER Admissions 1.13 (0.71, 1.81) 0.60 1.18 (0.82, 1.70) 0.37
Inpatient Admissions 0.90 (0.62, 1.31) 0.58 0.95 (0.72, 1.26) 0.73
Diabetes Complications 0.89 (0.74, 1.07) 0.22 0.90 (0.78, 1.04) 0.16
Count of OAD Classes 0.99 (0.96, 1.03) 0.60 1.04 (1.01, 1.06) 0.01
Macrovascular Complications 1.03 (0.87, 1.21) 0.75 0.89 (0.78, 1.01) 0.08
Mental Health Disorders 0.76 (0.55, 1.04) 0.08 0.81 (0.64, 1.02) 0.08
Average Copay for Insulin 0.99 (0.98, 0.99) <0.0001 0.99 (0.99, 0.99) <0.0001
Reference Groups: Age 45-54, Region: NorthEast, Non-Capitated Insurance
Abbreviation: Com Inex = Comorbidity Index; OAD = oral antidiabetic agents; OR = odds ratio;
CI = Confidence Interval.
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somewhat different nature of the injection. However,
this study failed to find a statistically significant relation-
ship between insulin pen use and persistence, similar to
the findings of Pawaskar and colleague [15]. This finding
may be partly due to the availability of products and the
study timeframe. At the same time, the greater dosing
flexibility may have contributed to the consistent asso-
ciation between analog insulin and increased persis-
tence. This current analysis could not, however, control
for provider-related characteristics or preferences that
may be related to insulin persistence and the use of
human versus analog or pen versus vial/syringe insulin.
The finding that higher counts of concomitant dia-
betes medications were positively associated with insulin
persistence is inconsistent with existing literature [10].
This association could be due, in part, to the fact that
the use of additional classes of OAD agents are a result
of healthcare utilization and monitoring. It is also possi-
ble that collinearity between the count of OAD classes
and diabetes complications is interfering with the multi-
variate models. This may explain the change in direction
from the univariate to the multivariate results.
Caution should be used when interpreting the results
of persistency to insulin therapy. There is no validated
measure available to measure insulin adherence and per-
sistence. The presence of a claim gap (measure 1) is
a commonly used measure for persistency [16]. The ori-
ginal formulation of measure 2 incorporated the current
number of claims structure and a requirement of
0.10 mL index insulin per day, on average. Descriptive
analyses of the average quantity of insulin per day did
not provide a clear, clinically relevant cut-off that did
not appear arbitrary. Descriptive analysis also indicated
that the number of claims requirement, as opposed to
the insulin quantity per day, largely determined persis-
tence status. Both of these reasons support excluding
insulin quantity per day from persistence determination.
By either measure, non-persistence indicates a signifi-
cant break in a patient’s use of mealtime insulin that is
reflected both in time off of therapy and in average daily
dose of insulin. Non-persistent patients had an average
total daily insulin dose of 0.30 mL (non-persistent by
measure 1) and 0.27 mL (non-persistent by measure 2),
which included average daily mealtime insulin dose per
day of 0.13 mL and 0.10 mL, respectively. While the
recommended quantity of mealtime insulin per day dif-
fers by patient, these levels are significantly lower than
would be expected in a group of patients with adequately
managed type 2 diabetes using mealtime insulin [17,18].
The Thomson Reuters MarketScan® research data-
bases are comprised of only adjudicated claims; this
minimizes, but not completely removes, the risk of
incomplete, missing, or miscoded claims impacting the
study findings. Errors present are likely random and
independent of the study outcomes and cohorts, further
minimizing their potential impact on the study.
A related and significant limitation is the lack of records
involving services that do not drive a service payment.
Lab values (including hemoglobin A1C), patient bio-
metric measures, and a record of free insulin samples
are some of the key missing data fields. Further, the
database contains very little information regarding phy-
sician behavior, training, or patient instructions, making
it impossible to investigate or control for physician-level
factors, including physician tendencies to prescribe
more or less insulin per visit.
Conclusions
In a cohort of patients intensifying their basal insulin
therapy with the addition of mealtime insulin, use was
lower than expected in terms of quantity per day, num-
ber of claims, and persistence. In Addition, persistence
to mealtime insulin decreases over time. Persistence to
human insulin was considerably lower than the analog
insulin. Elderly age, human insulin use, increased aver-
age insulin copayment, mental health comorbidity, and
polypharmacy were all consistent predictors of poorer
persistence with mealtime insulin.
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